The US accounted for the remaining 46% of the sales, which were affected due to the generic competition to anti-seizure drug Lyrica. International markets contributed to 54% of the company’s revenues that were driven by the sales of anti-infective products in China, including its antibiotic drug Sulperazon. Pfizer recorded a 4% decline in revenues with the biopharma segment accounting for 76.2% of the revenues. Image courtesy of Michael Vi/Shutterstock. Pfizer – $51.75bn The US contributed to 46% of Pfizer’s sales in 2019. Based on the results, the first batches of the vaccine are expected to be available in the first quarter of 2021 for emergency use. Clinical trials were commenced in September 2020 with data expected to be available in December 2020. The vaccine candidate was announced in March 2020 and entered pre-manufacturing in June 2020. J&J is working towards the development of a COVID-19 vaccine through the Ad26® vector technology and PER.C6® manufacturing platform. The majority of the categories of the consumer health segment are anticipated to perform well, although certain categories may be impacted due to reduced store visits and social distancing behaviours. J&J expects minor disruption to its pharmaceutical business in 2020 although growth is projected to remain above market growth. Some of the new prescription drugs approved during the year included BALVERSA™ (erdafitinib), XARELTO® (rivaroxaban), SPRAVATO® (esketamine), INVOKANA® (canagliflozin) and STELARA® (ustekinumab). Revenues of the pharmaceutical division grew by 3.6%, driven by the immunology ($13.95bn) and oncology ($10.69bn) portfolio. Johnson & Johnson’s (J&J) consumer health segment recorded a 0.3% increase in revenues, majorly contributed by sales in the US market along with acquisitions and divestitures, which had a positive impact of 1.6% on sales growth. Image courtesy of Johnson & Johnson Services, Inc. Johnson & Johnson – $56.1bn Johnson & Johnson is currently involved in development of a vaccine to fight the COVID-19 disease. Shanghai Pharmaceuticals Holding – $26.69bn 1.
0 Comments
Leave a Reply. |